Clinical Studies

A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D

You are here

At the American Diabetes Association 80th Scientific Sessions, researchers from Dexcom presented the latest findings on a study of the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The research looked at glycemic and quality of life indicators for a cohort of 39 commercially insured adults with T2D (age 25-65)* who were managed with intensive insulin therapy and used CGM for at least 12 weeks. Watch the five-minute poster presentation below. 

The study is still ongoing, and we look forward to publishing full results in the coming months.    

 

*Prior to participating in any study procedures, each subject was asked to voluntarily document their consent by signing an Institutional Review Board (IRB) approved informed consent form.
Noar, A, Welsh J, Price D. A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D. Presented at ADA 80th Scientific Sessions; June 12, 2020; Virtual.   

More Clinical Studies

This paper reviews the features and available evidence supporting use of both real-time continuous glucose monitoring (rtCGM) and intermittent scanning CGM (isCGM), offering guidance for patient selection for each type of system. RtCGM systems (...

HypoDE study shows that Dexcom CGM use significantly reduces hypoglycemia in MDI patients.1 Background

Continuous glucose monitoring (CGM) clinical trials to date have largely excluded individuals with severe hypoglycemia (SH) or...

In hypoglycemia unaware patients, CGM provides the required information needed for enhanced decision making support to improve glycemic control and help eliminate severe hypoglycemia. In this observational study, severe hypoglycemia incidents...